NCT02460276View on ClinicalTrials.gov

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Relapsed/Refractory Mantle Cell Lymphoma
Interventions
DRUG

Lenalidomide

DRUG

Ibrutinib

DRUG

Rituximab

Trial Locations (5)

Unknown

Rigshospitalet, Copenhagen

Helsinki University Hospital, Helsinki

0424

Norwegian Radium Hospital, Oslo

221 85

Lund University Hospital, Lund

751 85

Uppsala Akademiska Hospital, Uppsala

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Janssen, LP

INDUSTRY

collaborator

Nordic Lymphoma Group

NETWORK

lead

Lund University Hospital

OTHER